# Open Label Extension Study to Assess the Safety and Long-Term Immunogenicity of ARCT-021

> **NCT04728347** · PHASE2 · TERMINATED · sponsor: **Arcturus Therapeutics, Inc.** · enrollment: 65 (actual)

## Conditions studied

- SARS-CoV-2

## Interventions

- **BIOLOGICAL:** ARCT-021

## Key facts

- **NCT ID:** NCT04728347
- **Lead sponsor:** Arcturus Therapeutics, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2021-01-04
- **Primary completion:** 2021-12-28
- **Final completion:** 2021-12-28
- **Target enrollment:** 65 (ACTUAL)
- **Why stopped:** A decision was made to terminate the study for operational/business reasons. This study was not terminated for reasons of safety or immunogenicity.
- **Last updated:** 2024-12-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04728347

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04728347, "Open Label Extension Study to Assess the Safety and Long-Term Immunogenicity of ARCT-021". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT04728347. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*